(Q37092262)

18 August 2017

title

Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia (English)

1 reference

18 August 2017

Patrick J Gallegos

1

1 reference

18 August 2017

Lawrence A Frazee

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

28

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

356-365

1 reference

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Urinary incontinence in the community--analysis of a MORI poll

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicen

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

Drug therapy of urinary urge incontinence: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.3.356

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.3.356

1 reference

18 August 2017

1 reference